• SENSEX
    NIFTY 50
Business

Confident of addressing 3 USFDA observations for Malaysia unit expeditiously, says Biocon

Updated : February 24, 2020 11:33 AM IST

In a position to launch insulin glargine in H2CY20 with Mylan.
Transition from NDA to BLA for certain biologics will not impact Co's submission.

You May Also Like

Live TV
Advertisement